News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Vectura Group plc Announces Successful Outcome Of Phase II Study On Inhaled Parkinson’s Disease Product – VR040
August 8, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Vectura Group plc (LSE: VEC) (“Vectura”) today announces the successful outcome of a Phase II “proof-of concept” clinical study for its product, VR040, for the treatment of induced “off” periods in patients with Parkinson’s disease (PD).
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Cancer
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep
December 15, 2025
·
2 min read
·
Heather McKenzie
Autoimmune disease
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership
December 15, 2025
·
1 min read
·
Annalee Armstrong
Autoimmune disease
Argenyx’s Vyvgart Flops Phase III Thyroid Eye Disease Test, Raising Risk for Ongoing Trials
December 15, 2025
·
1 min read
·
Annalee Armstrong
Multiple sclerosis
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application
December 15, 2025
·
2 min read
·
Annalee Armstrong
